-
1
-
-
77951089891
-
-
International Diabetes Federation Accessed January 20
-
International Diabetes Federation. IDF Diabetes Atlas (6th edition). http://www.idf.org/sites/default/files/Atlas-poster-2014-EN.pdf. Accessed January 20, 2015.
-
(2015)
IDF Diabetes Atlas (6th Edition)
-
-
-
2
-
-
35748967622
-
-
Ministry of Health, Labor and Welfare Accessed January 20, 2015
-
Ministry of Health, Labor and Welfare. The National Health and Nutrition Survey in Japan, 2012. http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h24-houkoku.pdf. Accessed January 20, 2015.
-
(2012)
The National Health and Nutrition Survey in Japan
-
-
-
4
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
-
I.M. Stratton, A.I. Adler, H.A. Neil, and et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
-
(2000)
BMJ
, vol.321
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
5
-
-
0142087597
-
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study
-
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study JAMA 290 2003 2159 2167
-
(2003)
JAMA
, vol.290
, pp. 2159-2167
-
-
-
6
-
-
84888214461
-
Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria
-
H. Yokoyama, S. Araki, J. Honjo, and et al. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria Diabetes Care 36 2013 3227 3233
-
(2013)
Diabetes Care
, vol.36
, pp. 3227-3233
-
-
Yokoyama, H.1
Araki, S.2
Honjo, J.3
-
7
-
-
84878598114
-
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD
-
Kidney disease improving global outcomes KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD Kidney Int 3 suppl 2013 91 111
-
(2013)
Kidney Int
, vol.3
, pp. 91-111
-
-
-
9
-
-
84954405080
-
-
Committee on the Proper Use of Biguanides revision at March 28, 2014. Accessed April 1
-
Committee on the Proper Use of Biguanides. Recommendation on the proper use of biguanides, revision at March 28, 2014. http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025-7265636F6D6D656E646174696F6E5F62696775616E6964652E706466. Accessed April 1, 2015.
-
(2015)
Recommendation on the Proper Use of Biguanides
-
-
-
10
-
-
77951143723
-
(1S)-1,5-anhydro-1- [45-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment
-
H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, and et al. (1S)-1,5-anhydro-1- [45-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment J Med Chem 53 2010 3247 3261
-
(2010)
J Med Chem
, vol.53
, pp. 3247-3261
-
-
Kakinuma, H.1
Oi, T.2
Hashimoto-Tsuchiya, Y.3
-
11
-
-
79961228970
-
TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
-
K. Yamamoto, S. Uchida, K. Kitano, and et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity Br J Pharmacol 164 2011 181 191
-
(2011)
Br J Pharmacol
, vol.164
, pp. 181-191
-
-
Yamamoto, K.1
Uchida, S.2
Kitano, K.3
-
12
-
-
84911028030
-
Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes
-
B. Peene, and K. Benhalima Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Ther Adv Endocrinol Metab 5 2014 124 136
-
(2014)
Ther Adv Endocrinol Metab
, vol.5
, pp. 124-136
-
-
Peene, B.1
Benhalima, K.2
-
13
-
-
84902245089
-
Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A 12-week, randomized, placebo-controlled, phase II study
-
Y. Seino, T. Sasaki, A. Fukatsu, and et al. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study Curr Med Res Opin 30 2014 1219 1230
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 1219-1230
-
-
Seino, Y.1
Sasaki, T.2
Fukatsu, A.3
-
14
-
-
84902242668
-
Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: A 12-week, randomized, double-blind, placebo-controlled, phase II study
-
Y. Seino, T. Sasaki, A. Fukatsu, and et al. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study Curr Med Res Opin 30 2014 1231 1244
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 1231-1244
-
-
Seino, Y.1
Sasaki, T.2
Fukatsu, A.3
-
15
-
-
84903557735
-
Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study
-
Y. Seino, T. Sasaki, A. Fukatsu, and et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study Curr Med Res Opin 30 2014 1245 1255
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 1245-1255
-
-
Seino, Y.1
Sasaki, T.2
Fukatsu, A.3
-
16
-
-
84933675778
-
Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
-
Y. Seino, N. Inagaki, M. Haneda, and et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus J Diabetes Invest 6 2015 443 453
-
(2015)
J Diabetes Invest
, vol.6
, pp. 443-453
-
-
Seino, Y.1
Inagaki, N.2
Haneda, M.3
-
17
-
-
84938319426
-
Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
-
Y. Seino, K. Kaku, N. Inagaki, and et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise Endocr J 62 2015 593 603
-
(2015)
Endocr J
, vol.62
, pp. 593-603
-
-
Seino, Y.1
Kaku, K.2
Inagaki, N.3
-
18
-
-
84882591638
-
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
-
S. Kasichayanula, X. Liu, M. Pe Benito, and et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus Br J Clin Pharmacol 76 2013 432 444
-
(2013)
Br J Clin Pharmacol
, vol.76
, pp. 432-444
-
-
Kasichayanula, S.1
Liu, X.2
Pe Benito, M.3
-
19
-
-
84919333505
-
Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment
-
N. Inagaki, K. Kondo, T. Yoshinari, and et al. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment Clin Drug Investig 34 2014 731 742
-
(2014)
Clin Drug Investig
, vol.34
, pp. 731-742
-
-
Inagaki, N.1
Kondo, K.2
Yoshinari, T.3
-
20
-
-
84911874621
-
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus
-
A. Sarashina, K. Ueki, T. Sasaki, and et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus Clin Ther 36 2014 1606 1615
-
(2014)
Clin Ther
, vol.36
, pp. 1606-1615
-
-
Sarashina, A.1
Ueki, K.2
Sasaki, T.3
-
21
-
-
84893727925
-
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
-
S. Macha, M. Mattheus, A. Halabi, and et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment Diabetes Obes Metab 16 2014 215 222
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 215-222
-
-
MacHa, S.1
Mattheus, M.2
Halabi, A.3
-
22
-
-
84876803427
-
Renal glucose handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
-
E. Ferrannini, S.A. Veltkamp, R.A. Smulders, and T. Kadokura Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes Diabetes Care 36 2013 1260 1265
-
(2013)
Diabetes Care
, vol.36
, pp. 1260-1265
-
-
Ferrannini, E.1
Veltkamp, S.A.2
Smulders, R.A.3
Kadokura, T.4
-
23
-
-
65549111017
-
Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan
-
S. Matsuo, E. Imai, M. Horio, and et al. Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan Am J Kidney Dis 53 2009 982 992
-
(2009)
Am J Kidney Dis
, vol.53
, pp. 982-992
-
-
Matsuo, S.1
Imai, E.2
Horio, M.3
-
24
-
-
84857217561
-
Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values
-
A. Kashiwagi, M. Kasuga, E. Araki, and et al. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values J Diabetes Investig 3 2012 39 40
-
(2012)
J Diabetes Investig
, vol.3
, pp. 39-40
-
-
Kashiwagi, A.1
Kasuga, M.2
Araki, E.3
-
25
-
-
84897394040
-
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
-
D.E. Kohan, P. Fioretto, W. Tang, and J.F. List Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Kidney Int 85 2014 962 971
-
(2014)
Kidney Int
, vol.85
, pp. 962-971
-
-
Kohan, D.E.1
Fioretto, P.2
Tang, W.3
List, J.F.4
-
26
-
-
84876311251
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
-
J.F. Yale, G. Bakris, B. Cariou, and et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 2013 463 473
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 463-473
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
27
-
-
84904525477
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy
-
H. Yamout, V. Perkovic, M. Davies, and et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy Am J Nephrol 40 2014 64 74
-
(2014)
Am J Nephrol
, vol.40
, pp. 64-74
-
-
Yamout, H.1
Perkovic, V.2
Davies, M.3
-
28
-
-
84899961819
-
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial
-
A.H. Barnett, A. Mithal, J. Manassie, et al. EMPA-REG RENAL Trial Investigators Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2 2014 369 384
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 369-384
-
-
Barnett, A.H.1
Mithal, A.2
Manassie, J.3
-
29
-
-
33845340507
-
Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis
-
Z.T. Bloomgarden, R. Dodis, C.M. Viscoli, and et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis Diabetes Care 29 2006 2137 2139
-
(2006)
Diabetes Care
, vol.29
, pp. 2137-2139
-
-
Bloomgarden, Z.T.1
Dodis, R.2
Viscoli, C.M.3
-
30
-
-
80053920805
-
Metabolic syndrome and kidney disease: A systematic review and meta-analysis
-
G. Thomas, A.R. Sehgal, S.R. Kashyap, and et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 6 2011 2364 2373
-
(2011)
Clin J Am Soc Nephrol
, vol.6
, pp. 2364-2373
-
-
Thomas, G.1
Sehgal, A.R.2
Kashyap, S.R.3
-
31
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study(UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
32
-
-
77955585592
-
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial
-
F. Ismail-Beigi, T. Craven, M.A. Banerji, et al. ACCORD Trial Group Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 2010 419 430
-
(2010)
Lancet
, vol.376
, pp. 419-430
-
-
Ismail-Beigi, F.1
Craven, T.2
Banerji, M.A.3
-
33
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
ADVANCE Collaborative Group A. Patel, S. MacMahon, J. Chalmers, and et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
-
(2008)
N Engl J Med
, vol.358
, pp. 2560-2572
-
-
Patel, A.1
MacMahon, S.2
Chalmers, J.3
-
34
-
-
58149389215
-
Glucose control and vascular complications in veterans with type 2 diabetes
-
W. Duckworth, C. Abraira, T. Moritz, et al. VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
-
(2009)
N Engl J Med
, vol.360
, pp. 129-139
-
-
Duckworth, W.1
Abraira, C.2
Moritz, T.3
-
35
-
-
79960959816
-
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials
-
R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi, and et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials BMJ 343 2011 d4169
-
(2011)
BMJ
, vol.343
, pp. d4169
-
-
Boussageon, R.1
Bejan-Angoulvant, T.2
Saadatian-Elahi, M.3
-
36
-
-
80052344301
-
Seasonal variation in estimated glomerular filtration rate based on serum creatinine levels in hypertensive patients
-
H. Masugata, S. Senda, M. Inukai, and et al. Seasonal variation in estimated glomerular filtration rate based on serum creatinine levels in hypertensive patients Tohoku J Exp Med 224 2011 137 142
-
(2011)
Tohoku J Exp Med
, vol.224
, pp. 137-142
-
-
Masugata, H.1
Senda, S.2
Inukai, M.3
-
37
-
-
0021948044
-
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass
-
S. Anderson, T.W. Meyer, H.G. Rennke, and B.M. Brenner Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass J Clin Invest 76 1985 612 619
-
(1985)
J Clin Invest
, vol.76
, pp. 612-619
-
-
Anderson, S.1
Meyer, T.W.2
Rennke, H.G.3
Brenner, B.M.4
-
38
-
-
84893214045
-
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
-
D.Z. Cherney, B.A. Perkins, N. Soleymanlou, and et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 129 2014 587 597
-
(2014)
Circulation
, vol.129
, pp. 587-597
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
-
39
-
-
84954370892
-
-
The Japanese Society of Hypertension. Accessed January 20
-
The Japanese Society of Hypertension. http://www.jpnsh.jp/data/jsh2014/jsh2014v1-1.pdf. Accessed January 20, 2015.
-
(2015)
-
-
-
40
-
-
78651112164
-
Hypertension in diabetic nephropathy: Epidemiology, mechanisms, and management
-
P.N. Van Buren, and R. Toto Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management Adv Chronic Kidney Dis 18 2011 28 41
-
(2011)
Adv Chronic Kidney Dis
, vol.18
, pp. 28-41
-
-
Van Buren, P.N.1
Toto, R.2
|